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ABSTRAK
Latar belakang: saat ini terdapat tiga jenis kelasi besi yang tersedia untuk pasien di Indonesia: deferiprone/
DFP (dengan merk dagang Ferriprox), deferasirox/DFX (dengan merk dagang Exjade) and deferoxamine/DFO 
(dengan merk dagang Desferal). Tujuan dari studi ini adalah untuk melihat kelasi besi mana yang paling efisien 
dalam menurunkan kelebihan besi pada miokard dan hepar yang dilihat dari hasil T2* MRI. Metode: pencarian 
jurnal dengan terminologi MeSH dilakukan di PubMed dan Scopus. Studi pada pasien thalassemia mayor di 
semua umur yang menggunakan monoterapi kelasi besi dan melihat efeknya pada T2* MRI liver atau miokard 
diikutkan ke dalam analisis. Penilaian dari studi yang digunakan dilakukan dengan metoda penilaian studi dari 
Oxford’s CEBM dan Joana Brigs Institute. Hasil: total 11 studi dengan jumlah total 611 sampel diikutkan dalam 
analisa studi ini. Nilai rerata T2* MRI dan (jika tersedia) nilai rerata perubahan T2* MRI setelah penggunaan 
satu jenis kelasi besi dianalisa dari semua studi yang diikutkan. Studi komparasi maupun studi individu menemukan 
kontrol dan peningkatan miokardiak T2* MRI pada sampel menggunakan DFP, sedangkan penggunaan DFO 
yang taat lebih baik dalam mengontrol dan meningkatkan liver T2* MRI. Kesimpulan: DFP lebih superior dalam 
mengontrol dan menurunkan beban besi miokard (dibuktikan oleh miokardial T2* MRI) sedangkan DFO memiliki 
kemampuan lebih baik dalam mengontrol dan menurunkan beban besi pada hepar (dibuktikan oleh liver T2* MRI). 
Studi dengan waktu observasi lebih lama dan sampel yang lebih besar dibutuhkan untuk melihat efek signifikan 
DFX terhadap T2* MRI.
Kata kunci: besi, talasemia, T2* MRI.
ABSTRACT
Background: there are currently three iron chelator readily available for patients Indonesia; deferiprone/
DFP (branded as Ferriprox), deferasirox/DFX (branded as Exjade) and deferoxamine/DFO (branded as 
Desferal). This study aims to determine which iron chelator is the most efficient in reducing cardiac and hepatic 
iron overload (measured by means of T2* MRI). Methods: journal search with determined MeSH term was done 
in PubMed and Scopus. Studies that looked upon thalassemia major patient in all ages with usage of monotherapy 
iron chelation and its effect on myocardial T2* MRI and/or liver T2* MRI was included. Appraisal of studies 
was done using Oxford’s CEBM appraisal tools and Joanna Brigs Institute critical appraisal tools. Results: 
total of 11 studies with grand total of 611 samples were included. Mean T2* MRI value or (when available) 
mean changes in T2* MRI value after usage of specific iron chelator was gained from all the studies included. 
Comparison study and individual studies shows better control and increase of myocardial T2* MRI in those 
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with DFP, and of liver T2* in those with good adherence to DFO chelation. Conclusion: DFP is superior in 
controlling or reducing myocardial iron load (as proven by mT2* MRI) and DFO had better capabilities in 
controlling or reducing hepatic iron load (as proven by liver T2* MRI). Studies with longer observation and 
larger samples is needed to see a significant changes of T2* MRI in DFX.
Keywords: iron chelation, thalassemia, T2* MRI.
INTRODUCTION
Iron overload (hemochromatosis) is a 
condition of excess iron accumulation in the 
body from any cause, one of them being repeated 
blood transfusions.1 In patients who needs 
frequent and/or continuous blood transfusion 
(e.g. Sickle cell anaemia, thalassemia, aplastic 
anaemia, leukaemia, etc), excess iron from donor 
blood accumulate and in time manifest itself 
into transfusional hemosiderosis in which iron 
accumulates in the liver, heart and endocrine 
organs causing clinical syndromes such as 
cardiomyopathy, diabetes and hepatic cirrhosis.
In order to prevent manifestation of excess 
iron into diseases, iron chelator had long 
been used. There are currently three different 
types of iron chelator readily available for 
patients Indonesia; deferiprone/DFP (branded as 
Ferriprox), deferasirox/DFX (branded as Exjade) 
and deferoxamine/DFO (branded as Desferal). 
Each of the three chelator offers different benefits 
and challenges to the patients; DFP comes in 
tablet (500 mg/tab) or syrup (100mg/mL) which 
makes it easier for children to consume, DFX are 
also available in 250 and 500 mg/tablet form, 
DFO is the first iron chelator available for use 
in RSCM but it can only be administered via 
subcutaneous (sc) or intravenous (iv) injection 
thus explaining its unpopularity and low 
compliance.2
There are different means of assessing iron 
overload in patients; simple blood examination 
(total iron binding capacity/TIBC, serum iron/
SI, transferrin saturation/TS and serum ferritin/
SF) and radiology (T2* MRI). As a more reliable 
mean to predict iron overload in organ (especially 
heart and liver), T2* MRI had been meticulously 
used to assess hemosiderosis and whether dose 
adjustment or combination iron chelation therapy 
is needed.2
There are studies available that assess 
the benefits of all different iron chelator; 
Luangasanatip et al1 and Pepe et al2 both uses 
Quality Adjusted Life Years (QALY) assessment 
to see economic benefits of each drugs, Xia 
et al3 look upon serum ferritin (SF), liver iron 
concentration (LIC), myocardial iron content 
(MIC), left ventricular ejection fraction (LVEF) 
and adverse events (AEs) as means of assessing 
effectiveness of each different iron chelator. Yet 
the question still remains, which iron chelator is 
the most efficient in regards to reducing cardiac 
and hepatic iron overload through assessment 
via T2* MRI.
CLINICAL QUESTION
11-year-old boy with beta-thalassemia major, 
had been receiving continuous blood transfusion. 
His recent T2* MRI result shows a moderate 
hepatic and myocardial iron load. Previous 
doctor prescribed DFO for the last 3 years, but 
compliance level had been very low due to the 
hassle of sc administration. Current attending 
doctor decided to prescribed oral DFP with hopes 
that compliance level may increase and his body 
iron load can be controlled. The patient parents 
become concern with the change of iron chelator 
and T2* MRI results, they asked whether the oral 
drug given is more effective compared to the sc 
ones their child had been using.
From the case illustration, a clinical question 
arises: “Which of the three iron chelator (DFP, 
DFX, DFO) is the most effective in reducing 
cardiac and hepatic iron load proven by means 
of T2* MRI?”
METHODS
This review will consider all in vivo studies 
in human subjects of any age who suffers from 
thalassemia. Intervention includes usage of DFP 
and/or DFX and/or DFO monotherapy in any 
dose. Those on combination iron chelator aren’t 
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going to be included. Outcome measure wanted 
are T2* MRI that assess both/either hepatic or 
cardiac iron load. All Randomized Control Trial 
(RCT), prospective study, retrospective study, 
cross-sectional study with full text available in 
English or Indonesian since 20 years ago will 
be included.
Search Strategy
The initial search terms will be ‘iron 
chelator’, ‘MRI T2*’, ‘thalassemia’, followed 
by proper MeSH search (Table 1). Articles 
published in the following databases will be 
searched: PubMed and Scopus. Full copies of 
articles identified by the search, and considered 
to meet the inclusion criteria, based on their title, 
abstract and subject descriptors, will be critically 
appraised.
RESULTS
Summary of the literature search process 
and result can be seen in Figure 1. This study 
included 6 prospective studies, 1 randomized 
control trial, 1 prospective-comparative studies, 
2 cross-sectional studies and 1 retrospective 
studies. In total, 11 studies are included with a 
total of 611 patients using different monotherapy 
of either DFP, DFO or DFX. All the studies 
used adhere to the criteria that is set by the 
Table 1. Search strategy and MeSH term used
Database Search terms Hits Selected article
PubMed/Scopus
(“iron”[MeSH terms] OR “iron”[All Fields]) AND (“chelating agents” 
[Pharmacological Action] OR “chelating agents” [MeSH Terms] OR (“chelating” 
[All Fields] AND “agents” [All Fields]) OR “chelating agents” [All Fields] OR 
“chelator” [All Fields]) AND (“thalassemia” [All Fields] OR “thalassemia” [MESH 
Terms] OR “thalassemia” [All Fields]) AND (“magnetic resonance imaging” 
[MeSH Terms] OR (“magnetic” [All Fields] AND “resonance” [All Fields] AND 
“imaging” [All Fields]) OR “magnetic resonance imaging” [All Fields] OR “mri” 
[All Fields]) and t2 [All Fields
140 10
Figure 1. Flowchart of search result
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Joanna Briggs Institute (JBI) critical appraisal 
tools (for randomized control trial, cohort and 
cross-sectional studies – respectively Appendix 
1, Appendix 2 and Appendix 3), summary 
of appraisal result can be seen in Table 3. 
Breakdown for sample allocation and chelator 
dosage of each study present in Table 2. Oxford 
CEBM appraisal of prognosis study was used to 
assess all of the studies, summary of the result 
can be seen in Table 4.
DISCUSSION
The aim of this evidence based case report 
was to evaluate the effectiveness of DFO, DFP, 
and DFX alone in reducing hepatic and cardiac 
iron load (proven by means of MRI T2* value) in 
transfusion-dependent patients with thalassemia 
major.
Table 2. Summary of studies included with years of publication, age range of samples and type of chelator used in each study







Prospective Study 2013 6-29 DFX 30 25-35 Ahmed et al4
Prospective-comparative 
Study
2016 5-18 DFX 17 30 Gomber et al5
  DFP 17 75  
Prospective Study 2017 16-79 DFX 53 up to 40 Ho et al6
Prospective Study 2011 6-29 DFX 30 20 increased to 35 Merchant et al7
Prospective Study 2010 10-29 DFX 19 20 Pathare et al8
Prospective Study 2010 13-28 DFX 101 92 Pennell et al9
Randomized Control Trial
2006 25-31 DFP 29 43 Pennell et al10
  DFO 32 33.6 ± 9.8  
Cross-sectional study
2006 19-39 DFP 18 75 Pepe et al11
  DFO 18 50  
Retrospective cohort
2011 19-41 DFP 42 72 ± 10 Pepe et al12
 DFO 89 30 ± 9  
 DFX 24 26 ± 6.3  
Prospective Study 2013 3-19 DFP 73 79.1 ± 4.3 Viprakasit et al13
Cross-sectional study
2013 1-17 DFP 14 75–100 Zachariah et al14
DFX 5 25–40
Table 3. Summary of study appraisal based on JBI appraisal checklist
Author Design
Score based on appropriate JBI appraisal* Overal 
appraisal1 2 3 4 5 6 7 8 9 10 11 12 13
Ahmed et al4 Prospective study Y Y Y Y Y Y Y Y Y N Y NA NA Included
Gomber et al5 Prospective study Y Y Y N N Y Y Y Y N Y NA NA Included
Ho et al6 Prospective study Y Y Y N N Y Y Y Y Y Y NA NA Included
Merchant et al7 Prospective study Y Y Y Y Y Y Y Y Y N Y NA NA Included
Pathare et al8 Prospective study Y Y Y Y N Y Y Y Y N Y NA NA Included
Pennell et al9 RCT U U Y U U U Y Y Y Y Y Y Y Included
Pennell et al10 Prospective study Y Y Y Y Y Y Y Y Y Y Y NA NA Included
Pepe et al11 Cross-section Y Y Y Y N N Y Y NA NA NA NA NA Included
Pepe et al12 Retrospective Y Y Y N N Y Y Y Y Y Y NA NA Included
Viprakasit et al13 Prospective study Y Y Y Y Y Y Y Y Y Y Y NA NA Included
Zachariah et al14 Cross-section Y Y Y Y Y N N Y NA NA NA NA NA Included
*Scored gained/maximum score, appropriate appraisal for either RCT, cohort (prospective or retrospective) or cross-sectional 
study was used. RCT - 13 criteria, cohort - 11 criteria, cross-section - 8 criteria.
Y=yes; N=no; U=unclear; NA=not applicable.
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Based upon study by Saggar et al15, normal 
MRI T2* range for iron deposition in several 
organs (namely pancreas, liver and myocardial) 
can be defined. In regards to myocardial T2* 
value; normal range is defined as >20 ms, mild 
to moderate as 10-20 ms while severe as <10 ms. 
Value for hepatic iron load is defined as; normal 
T2* value would be >6.3 ms, mild is defined as 
6.3-2.7 ms, moderate as 2.7-1.4 ms and severe 
<1.4 ms. These values would be used when 
talking about severity of siderosis for the sake 
of discussion in this study.
Myocardial T2* MRI
Looking upon usage of DFO alone, mean 
mT2* value from two studies (both by Pepe 
et al2) similarly shows 27.00 ms which can be 
defined as normal range of cardiac iron load. 
This result is very promising, considering that 
both study looked upon patients aged 19-41 years 
old where cardiac siderosis is usually already 
present (though not always as cardiac siderosis 
may be present at earlier age).16 Other study 
that looked upon DFO is Pennell’s randomized 
control trial, patient in this study had mild to 
moderate cardiac siderosis yet in the end of the 
study mean increase of 2.70 ms is observed in 
those treated with DFO. This result is in line 
with previous studies, namely by Borna-Pignatti 
et al17 that shows how iron-related heart disease 
had decreased after the introduction of DFO 
(with earlier therapy commencement being an 
important aspect). Anderson et al18 shows that 
3 months of continuous DFO (50-60mg/kgbw/
day) iv administration are able to normalize 
LVEF. Porter et al19, however, mentioned also 
that if mT2* <10 ms it would take a few years to 
normalize mT2* with continuous DFO infusion. 
DFP uses had somewhat been more preferable 
in many patients due to its ease of administration 
in oral form. Five studies (Gomber et al5, two of 
Pepe et al2 studies, Zachariah et al14 and Pennell 
et al10) looked upon the effectiveness of DFP 
in improving mT2*. Two of Pepe’s studies and 
Zachariah et al only had mean mT2* value; 35.00 
ms (Pepe’s cross-section), 34.00 ms (Pepe’s 
retrospective), 37.10 ms (Zachariah et al14). All 
of the results shows normal mT2* value, it should 
be noted that Pepe’s studies had patient from 19 
years of age – 41 years of age with pretty large 
sample size. Zachariah had noted that his study 
had a limitation of low sample (with only 14 
samples in DFP group). Gomber et al5, curiously, 
saw a decrease in mT2* by -1.00 ms, though the 
study found that this changes is insignificant and 
blame this unusual result to small sample size 
combined with relatively short follow up time 
(12 months). Pennell’s9 study had measurements 
of mT2* before and after iron chelation therapy; 
his sample includes patient with mild to moderate 
cardiac siderosis (13.00 ms) and after one year 
of DFP consumption significant (p-value <0.05) 
increase of 3.50 ms is observed. The benefits that 
DFP has on myocardium and cardiac function in 
general is in concordance with Maggio et al’s20 
study in which an improvement of left ventricular 
ejection fraction was observed in patients with 
DFP monotherapy.
There are seven studies that looked upon 
the effect of DFX on mT2*, these are studies by 
Gomber et al5, Ho et al6, Merchant et al7, Pathare 
et al8, Pennel et al9 (prospective study), Pepe et 
al11 (retrospective study) and Zachariah et al14. 
Gomber et al5 looked upon those with good cardiac 
iron load and saw an insignificant decrease of 0.30 
ms in mT2*, similar to what had been previously 
explained he blamed this odd results to sample 
size and follow up time. Ho et al also looked upon 
patient with good cardiac iron load and saw a 
significant increase of 2.18 ms after 12 months of 
DFX. Merchant et al saw an insignificant increase 
of 0.40 ms in patient with normal mT2*. Pathare 
et al8 saw an insignificant increase of 4.30 ms 
in patient with mild-moderate mT2*, the study 
mentioned that more sample would probably 
resulted in a statistically significant value. Pennel 
et al9,10 looked upon patient with mild-moderate 
mT2* and found a significant increase of 3.60 
ms. Pepe et al11 and Zachariah et al14 only had 
mean mT2* value of those with DFX chelator 
(respectively, 21.00 ms and 31.70 ms), both 
studies found good mT2* MRI value in all patients 
with DFX chelator.
There are five studies present with direct 
comparison between two or more chelators 
and these are studies done by Gomber et al5, 
Pennell et al9,10, both studies by Pepe et al11,12, 
and Zachariah et al14. Gomber et al5 compares 
DFP and DFX, results of his studies shows an 
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insignificant decrease (increase in iron load) in 
mT2* MRI for both DFP and DFX group (-1.00 
ms and -0.30 ms respectively), though this study 
mentioned a somewhat lower decrease in DFX 
group, the result is insignificant due to very 
small sample size. Pennell et al9,10 randomized 
control trial looked upon DFP and DFO use 
for 12 months and found a significant increase 
more favourable in those with DFP (increase 
of 3.50 ms compared to 2.70 ms), the study 
recommended a dose of around 90-100 mg/
kgbw/day in order to continually improve cardiac 
function (judged by increase in T2* MRI). Pepe 
et al9 cross sectional study found that mean T2* 
MRI is more favourable in those with continuous 
DFP usage (35.00 ms) compared to those with 
DFO infusion (27.00 ms). This result is similar 
to mechanism of DFP that is mentioned by Piga 
et al21, in this study DFP is deemed to be more 
effective in removing myocardial iron load due 
to its 10 fold higher capabilities in removing 
citrate bound iron (an important component 
of Non-transferin-bound iron/NTBI, a major 
contributor of iron damage). Previous effect is 
compounded by the fact that DFP has longer 
half-life and more frequent dosing (3 times/day, 
7 day/week) resulting in more iron protection 
compared to DFO (8-12 hour/day, 5-7 times per 
week). Pepe et al12 retrospective study looked 
upon mean mT2* MRI result on patients with 
all three different chelators with DFP having 
significantly higher mean mT2* value (34.00 ms) 
followed by DFO (27.00 ms) and DFX (21.00 
ms) resonating the results of previous studies. 
Zachariah et al14 further support the trend that 
DFP patients seems to have higher mT2* (37.10 
ms compared to 31.70 ms in DFX patient) which 
correlates with increase in patient’s cardiac 
function. In comparison to both DFX and DFO, 
DFP seems to be superior in removing iron from 
the myocardium due to several possible reasons; 
its higher capability to mobilize NTBI, longer 
time available in the blood stream. As studied 
and mentioned by Anderson et al18, DFP also had 
a smaller molecular weight, though this means 
that the iron-chelator complex is somewhat less 
stable, it allows DFP to penetrates easier into 
cells thus allowing removal of more iron from 
the myocardium.
Liver T2* MRI
Two studies both by Pepe et al looked upon 
the effect of DFO on liver T2* MRI value, with 
both study showing good mean MRI T2* value 
(12.00 ms and 10.90 ms). These observations are 
resonated by several studies, such as those by 
Brittenham et al  and Cappelini et al24, in which 
usage of DFO infusion at a dose of around 37 mg/
kgbb/day is enough to stabilize or even reduced 
LIC (liver iron content).
Three studies, two by Pepe et al12 and one 
by Viprakasit et al13, looked upon the mean liver 
T2* in patient with DFP chelator. Both study 
done by Pepe et al12 only presented mean liver 
T2* at one point in time with both showing mild 
siderosis in group with DFP chelation (3.70 ms 
in the cross-sectional study and 6.00 ms in the 
retrospective study). Viprakasit et al13 study 
showed more favourable result with an increase 
0.35 ms after one year of DFP consumption 
in patient with moderate hepatic siderosis. An 
older study by Fischer et al25 shows also that 
negative iron balance by means of LIC can only 
be achieved in 1/3 of the patient using 75 mg/
kgbw/day of DFP.
Three studies by Ahmed et al4, Gomber et al5 
and Pepe et al11 looked upon DFX effect on liver 
T2* value. Ahmed et al4 looked upon patient with 
moderate to severe liver T2* MRI and found an 
insignificant increase of 0.02 ms after 18 months 
of DFX administration. Gomber et al5 looked 
upon patient with mild liver T2* MRI and also 
found and insignificant increase of 0.30 after 12 
months of DFX administration. Pepe et al11 on the 
other hand looked upon mean liver T2* MRI in 
patient that had been consuming DFX and found 
a value of 5.50 (mild liver T2* MRI). This results 
resonates previous studies by Cappellini et al24 
who mentioned that only moderate reduction 
of LIC present in children under 6 years with 
average dose of 21.9 mg/kgbw/day.
Studies done by Gomber et al5, and two 
studies by Pepe et al11 compares mean liver T2* 
value between different chelators. Gomber et al5 
compares liver T2* value after 12 months of DFP 
or DFX, the study found insignificant change 
of 0.20 ms and 0.30 ms respectively in patient 
with mild liver siderosis. In Pepe et al’s cross-
sectional present only mean liver T2* value, 
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3.70 ms (mild siderosis) in group with DFP and 
12.00 ms (normal) in those with DFO. Pepe et 
al’s retrospective study resonates similar result 
(in regards to effectiveness and normal liver 
T2* in those with DFP); patient with DFO had 
mean liver T2* value of 10.90 ms (normal liver 
T2*), those with DFP had 6.60 ms (borderline 
normal T2*), and patient with DFX with 5.50 
ms (mild siderosis). Through these comparisons 
alone, it can be seen that patient with treatment 
of DFO had better mean liver T2* MRI and good 
improvement after continuous administration 
of either intravenous or subcutaneous DFO. 
Looking back upon the aforementioned studies 
by Cappellini et al24 and Britenham et al23, it can 
be seen that DFO do have superior capability of 
controlling and even reducing liver iron. Though 
it should always be taken into consideration that 
adherence to DFO therapy can sometimes be 
challenging to patient; as had been mentioned 
by Viprakasit et al13, Pennell et al10 whilst 
Olivieri et al26 found that compliance of oral 
chelation (DFP) can reach 95% while those with 
intravenous chelation (DFO) can only reach 72% 
compliance rate.
CONCLUSION
Through analysis done in this study it can 
be seen that DFP is superior in controlling or 
reducing myocardial iron load (as proven by 
mT2* MRI) and DFO had better capabilities 
in controlling hepatic iron load (as proven by 
liver T2* MRI). Usage of DFP or DFX, as oral 
chelator) is more preferable due to its ease of 
use, with several studies presenting higher 
compliance rate in patient with oral chelator 
compared to injection (sc or iv) chelator. Studies 
with longer observation and larger samples is 
needed to see a significant changes of T2* MRI 
in DFX.
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